Can anticarbamylated protein antibodies be used to support the diagnosis of systemic lupus erythematosus?

Basit Öğe Kaydı
dc.authorid0000-0003-4711-4921en_US
dc.authorid0000-0002-8084-2018en_US
dc.authorid0000-0003-0717-8365en_US
dc.authorid0000-0003-1202-5566en_US
dc.authorid0000-0003-0434-3206en_US
dc.authorid0000-0003-4530-2304en_US
dc.contributor.authorÖzdemir, Bahar
dc.contributor.authorErden, Abdulsamet
dc.contributor.authorErten, Şükran
dc.contributor.authorYeşil, Turan Hilmi
dc.contributor.authorAlışık, Murat
dc.contributor.authorKüçükşahin, Orhan
dc.date.accessioned2023-06-19T11:19:48Z
dc.date.available2023-06-19T11:19:48Z
dc.date.issued2021en_US
dc.departmentBAİBÜ, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.description.abstractAim: Autoantibody development plays an important role in the pathogenesis of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). In this study, we aimed to determine the diagnostic value of anticarbamylated protein antibody (anti-CarP) antibody in SLE and RA patients and its relationship with disease prognosis. Material & method: Fifty-seven SLE patients (F/M 50/7; median age 40.9 +/- 13.7; median disease duration 2 years) who met the 2012 SLICC SLE diagnostic criteria were included in the study. A total of 46 RA patients selected according to the 2010 ACR/EULAR diagnostic criteria (F/M 38/8; median age 54.2 +/- 12.4; median disease duration 2 years) were included. A total of 30 healthy individuals were selected as the control group. The anti-CarP antibody was studied by using human anticarbamylated protein antibody ELISA Kit (SunRedBio, Shanghai, China). Results: Anti-CarP antibody positivity was found to be 17.4% in RA patients (p < 0.001), 54.4% in SLE patients (p < 0.001) and 3.3% in the healthy control group. The anti-CarP antibody was determined to predict SLE patients with 54.4% sensitivity and 96.7% specificity compared with the healthy control group (area under the curve: 0.755; p < 0.001). Conclusion: Anti-CarP antibody positivity was significantly higher in the SLE patients compared with the healthy control and RA group. It has significant sensitivity and specificity in both SLE and RA patients compared with the healthy controls.en_US
dc.identifier.citationÖzdemir, B., Erden, A., Erten, Ş., Yeşil, T. H., Alışık, M., & Kucuksahin, O. (2021). Can anticarbamylated protein antibodies be used to support the diagnosis of systemic lupus erythematosus?. Biomarkers in Medicine, 15(14), 1253-1260.en_US
dc.identifier.doi10.2217/bmm-2021-0037
dc.identifier.endpage1260en_US
dc.identifier.issn1752-0363
dc.identifier.issn1752-0371
dc.identifier.issue14en_US
dc.identifier.pmid34488432en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1253en_US
dc.identifier.urihttp://dx.doi.org/10.2217/bmm-2021-0037
dc.identifier.urihttps://hdl.handle.net/20.500.12491/11141
dc.identifier.volume15en_US
dc.identifier.wosWOS:000693081000001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorAlışık, Murat
dc.language.isoenen_US
dc.publisherFuture Medicine Ltden_US
dc.relation.ispartofBiomarkers in Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnti-Carp Antibodyen_US
dc.subjectRheumatoid Arthritisen_US
dc.subjectSystemic Lupus Erythematosusen_US
dc.titleCan anticarbamylated protein antibodies be used to support the diagnosis of systemic lupus erythematosus?en_US
dc.typeArticleen_US

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Temel Tıp Bilimleri Bölümü Koleksiyonu